Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Proteome Sciences ( (GB:PRM) ).
Proteome Sciences plc announced new loan agreements totaling £1 million to enhance its operational capacity following a challenging biotech market period. The company has seen a strong increase in orders, particularly in its services business, and plans to use the funds to acquire a new mass spectrometer to meet growing demand. This strategic move is part of a broader effort to capitalize on its recent product launches, including the TMTpro 35plex tags, and to continue its expansion in the proteomics sector. Changes in the company’s board were also announced, with Christopher Pearce stepping in as Executive Chairman and Abdel Omari resigning as CFO, reflecting ongoing strategic adjustments.
More about Proteome Sciences
Proteome Sciences plc is a specialist provider of contract proteomics services that facilitate drug discovery, development, and biomarker identification. Utilizing proprietary workflows, the company excels in analyzing tissues, cells, and body fluids. It offers advanced methods such as SysQuant® and TMT®MS2 for identifying new targets and understanding biological activities, alongside capabilities for biomarker discovery through Super-Depletion and TMTcalibrator™ analysis.
YTD Price Performance: -38.63%
Average Trading Volume: 126,008
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £8.21M
See more insights into PRM stock on TipRanks’ Stock Analysis page.
